NCT02136862View on ClinicalTrials.gov

ATHENA: Natural History of Disease Study in Alport Syndrome Patients

CompletedOBSERVATIONAL
Enrollment

165

Participants

Timeline

Start Date

September 4, 2014

Primary Completion Date

December 18, 2017

Study Completion Date

December 18, 2017

Conditions
Alport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2
Trial Locations (15)

2305

New Lambton

3050

Parkville

10032

New York

44195

Cleveland

55455

Minneapolis

60631

Chicago

63110

St Louis

75093

Plano

84123

Salt Lake City

92120

San Diego

V6Z1Y6

Vancouver

M5G 2N2

Toronto

Unknown

Paris

Göttingen

NW3 2QG

London

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02136862 - ATHENA: Natural History of Disease Study in Alport Syndrome Patients | Biotech Hunter | Biotech Hunter